Become A Featured Company

Field Trip Health Ltd. Announces Opening of Field Trip Health Center in Atlanta, GA, as it Continues Expansion in the US

Ryan Allway

January 26th, 2021

Psychedelics

Field Trip Health Ltd. (CSE: FTRP, OTCBB: FTRPF) (“Field Trip”), a global leader in the development and delivery of psychedelic therapies, announced today the opening of their fifth location in the United States in the city of Atlanta, GA, one of many locations that Field Trip is planning to open in 2021. Located in the Glenwood Park neighborhood, the Atlanta location is the first Field Trip Health center to open this year, following the opening of Toronto, New York, Los Angeles and Chicago in 2020.

With the opening of the Atlanta location, Field Trip continues to execute on its strategy to demonstrate the efficacy and safety of psychedelic-enhanced therapies to promote mental and emotional health and well-being across the country. Psychedelic-enhanced therapies have the potential to transform lives by treating such mental health challenges as depression, anxiety and PTSD, leading to improved well-being, optimism and increased neural plasticity according to multiple evidence-based studies from world-class institutions across the globe.

Field Trip’s step-by-step, integrated treatment programs are medically supervised and utilize ketamine (a legal, dissociative psychedelic molecule) in conjunction with psychotherapy, mindfulness, and self-care in a comfortable, spa-like environment to support those struggling with depression and other mental health challenges. Each Field Trip Health center is thoughtfully and intentionally designed to promote healing and provide people with a calming space before, during, and after treatment, and Atlanta is no different.

A great deal of consideration and thought goes into making each Field Trip Health center suited for the community it serves. The design of the Atlanta location was heavily influenced by the neighborhood and its building’s historic architecture. The decor is welcoming yet preserves the gothic-style heritage from the building, and there are nods to the local community throughout the space to give it an authentic Atlanta feeling.

Ronan Levy, Field Trip’s Executive Chairman added: “Psychedelic medicine is in the midst of a renaissance, experiencing renewed interest from the medical and scientific community around the world; in large part because of the capacity of psychedelic therapies to help people experience a sense of renewal and rebirth. With the Atlanta location that sense of a renewal and rebirth goes a step further. By being part of the redevelopment of the Atlanta Stockade, a former prison complex with a long and intricate history, our Atlanta location takes this narrative of renewal, rebirth and renaissance a step further. We are delighted to take a once penal building it and turn into a center for healing, expansion and growth.”

Dr. Ryan Yermus, Field Trip Health’s Chief Clinical Officer commented: “With the opening of our Atlanta location, we continue to deliver best-in-class psychedelic therapies to communities in the US. With each new Field Trip Health center, we not only create incredible impact and healing, we also advance the knowledge and application of psychedelic-assisted therapies. We are incredibly excited to bring this treatment to the people of Atlanta.”

The address for the Atlanta clinic is 750 Glenwood Avenue, SE Building 200, Suite 210, Atlanta, GA 30316 and patients can book a consultation by phone (1-888-519-6016), email (atlanta@fieldtriphealth.com) or online at https://www.fieldtriphealth.com/locations/atlanta.

About Field Trip Health Ltd.

Field Trip is the global leader in the development and delivery of psychedelic therapies, with three components, Field Trip Discovery, Field Trip Health, and Field Trip Digital. Field Trip Discovery is leading the development of the next generation of psychedelic molecules and conducting advanced research on plant-based psychedelics, Field Trip Health clinics provide psychedelic-enhanced therapies, and Field Trip Digital is building the digital and technological tools to support psychedelic experiences and consciousness expansion. Field Trip helps people in the communities where we operate, allowing those seeking accelerated personal growth to use a simple, evidence-based approach to heal and heighten engagement with the world.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

Network Partners

Follow Us on Social Media

LinkedIn

About CFN Media Group

CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.

Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.

Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer

loading